Skip to content

US · EVAX · BIOTECHNOLOGY

Evaxion Biotech A/S (EVAX) intrinsic value and stock valuation

$2.25as of 2026-11-21 · Mkt cap 18.82M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Evaxion Biotech A/S DCF and intrinsic value

InvestorsCraft values EVAX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from EVAX’s statements →

Evaxion Biotech A/S Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Horsholm, ND 2970 evaxion.ai

How the business is doing

Fiscal 2018–2025, USD

Revenue
$7.53M
20182025
Net income
-$-7.71M
20182025
Free cash flow
-$-6.66M
20182025
Total equity
$17M+19.3% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$7.53M$3.34M$70K$0.00$0.00
Operating income-$-9.23M-$-14.73M-$-22.2M-$-25.26M-$-25.83M
Net income-$-7.71M-$-10.57M-$-22.12M-$-23.17M-$-24.53M
EPSd-$-1.2M-$-9.88M-$-32.53M-$-39.27M-$-50.06M
Operating cash flow-$-6.65M-$-12.94M-$-17.69M-$-25.77M-$-21.93M
Capital expenditure-$-10K$0.00-$-90K-$-290K-$-1.36M
Free cash flow-$-6.66M-$-12.94M-$-17.78M-$-26.07M-$-23.29M
Total assets$28.4M$12.5M$12.9M$22M$40.2M
Total debt$7.5M$10.1M$10.9M$10.3M$3.69M
Net debt-$-15.73M$5.05M$5.29M-$-2.93M-$-28.48M
Total equity$17M-$-1.65M-$-4.73M$8.3M$32.4M
Cash and short-term investments$23.2M$5.05M$5.58M$13.2M$32.2M
Income statement
20252024202320222021
Revenue$7.53M$3.34M$70K$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$7.53M$3.34M$70K$0.00$0.00
Research and development expenses$9.97M$10.5M$11.9M$17.1M$19.6M
Selling, general and administrative expenses$6.49M$7.32M$10.1M$8.06M$6.18M
Other expenses$300K$300K$280K$140K$70K
Operating expenses$16.8M$18.1M$22.3M$25.3M$25.8M
Cost and expenses$16.8M$18.1M$22.3M$25.3M$25.8M
Interest income$300K$250K$150K$2.83M$2.04M
Interest expense$880K$960K$900K$1.51M$920K
Depreciation and amortization$610K$610K$610K$570K$340K
Ebitda-$-7.12M-$-9.79M-$-21.4M-$-22.57M-$-24.21M
Operating income-$-9.23M-$-14.73M-$-22.2M-$-25.26M-$-25.83M
Total other income/expenses, net$620K$3.38M-$-720K$1.32M$1.12M
Income before tax-$-8.62M-$-11.36M-$-22.91M-$-23.94M-$-24.71M
Income tax expense-$-910K-$-790K-$-790K-$-770K-$-180K
Net income-$-7.71M-$-10.57M-$-22.12M-$-23.17M-$-24.53M
Weighted average shares outstanding$6.41M$1.07M$680K$590K$490K
Weighted average diluted shares outstanding$6.41M$1.07M$680K$590K$490K
Balance sheet
20252024202320222021
Cash and short-term investments$23.2M$5.05M$5.58M$13.2M$32.2M
Net receivables$1.05M$1.86M$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$24.9M$8.77M$8.35M$17M$34.7M
Property, plant and equipment, net$3.32M$3.51M$4.34M$4.67M$5.17M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$90K
Long-term investments$0.00$40K$0.00$0.00$0.00
Total non-current assets$3.51M$3.72M$4.54M$5.04M$5.46M
Total assets$28.4M$12.5M$12.9M$22M$40.2M
Accounts payable$2.19M$2.97M$2.69M$2.08M$2.85M
Short-term debt$550K$470K$480K$440K$440K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.26M$4.37M$7.08M$3.76M$4.32M
Long-term debt$6.95M$9.63M$10.4M$9.82M$3.25M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$7.11M$9.77M$10.5M$9.96M$3.4M
Capital lease obligations$1.97M$1.93M$2.22M$2.25M$2.52M
Total liabilities$11.4M$14.1M$17.6M$13.7M$7.73M
Common stock$15.8M$10.5M$5.9M$3.89M$3.75M
Retained earnings-$-126.24M-$-118.54M-$-107.97M-$-85.84M-$-50.43M
Accumulated other comprehensive income (loss)$6.76M-$-3.6M$9.89M$9.53M-$-1.32M
Total equity$17M-$-1.65M-$-4.73M$8.3M$32.4M
Total investments$0.00$40K$0.00$0.00$0.00
Total debt$7.5M$10.1M$10.9M$10.3M$3.69M
Net debt-$-15.73M$5.05M$5.29M-$-2.93M-$-28.48M
Cash flow statement
20252024202320222021
Net income-$-7.73M-$-10.57M-$-22.12M-$-23.17M-$-24.53M
Depreciation and amortization$620K$610K$610K$570K$340K
Stock-based compensation$0.00$360K$480K$940K$1.38M
Change in working capital-$-140K$520K$1.56M-$-2.88M$1.24M
Accounts receivable$180K$370K$1.11M-$-1.49M$1.86M
Inventory$0.00$0.00$0.00$1.49M$0.00
Accounts payable-$-540K$450K$500K-$-600K-$-650K
Net cash provided by operating activities-$-6.65M-$-12.94M-$-17.69M-$-25.77M-$-21.93M
Investments in property, plant and equipment-$-10K$0.00-$-90K-$-290K-$-1.3M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-10K-$0.00-$-90K-$-270K-$-1.33M
Common stock issued$23.2M$16.6M$9.17M$430K$53.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$22.5M$13.1M$10.7M$7.85M$49.8M
Net change in cash$17.3M$370K-$-7.6M-$-18.98M$26.3M
Cash at end of period$23.2M$5.95M$5.58M$13.2M$32.2M
Operating cash flow-$-6.65M-$-12.94M-$-17.69M-$-25.77M-$-21.93M
Capital expenditure-$-10K$0.00-$-90K-$-290K-$-1.36M
Free cash flow-$-6.66M-$-12.94M-$-17.78M-$-26.07M-$-23.29M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Evaxion Biotech A/S

        Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.

        CEO
        Helen Katrina Tayton-Martin
        Employees
        46
        Beta
        0.26

        Explore

        Frequently asked questions

        What is the intrinsic value of Evaxion Biotech A/S (EVAX)?

        InvestorsCraft does not currently publish an intrinsic value for EVAX. How the IC value is calculated.

        Is EVAX undervalued?

        InvestorsCraft does not publish an undervaluation signal for EVAX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.